NCT04455568

Brief Summary

Heart disease is still one of the world's most important health problems, and it ranks second among the top ten causes of death among Taiwan. The main cause of death is acute coronary syndrome, and vascular stent placement is the main treatment method for acute coronary syndrome. The probability of restenosis in patients within half a year after a general stent is as high as 25% to 40%. Re-hospitalization and surgery is a big burden on patients and the country's medical costs. However, a set of convenient and accurate clinical tools to determine the prognosis of patients has not yet been developed. Miniaturized wearable devices have been the mainstream trend in medical development in recent years. ECG and heart sound analysis technology are an easy to used medical device for automatically calculating the parameters including EMAT (electromechanical activation time), S4, S4, SDI (Systolic dyssynchrony index). ECG and heart sound could evaluate the heart function, and has the potential to be an effective tools for prognosis and treatment guidelines. Heart rate variability (HRV) and Accelerationplethysmogram (APG) is also proved the predictive effect the outcome of patients. This study is start on June 1 2020. We will enroll 400 patients who diagnosis of acute coronary syndrome and have been a heart stent surgery, and registry there medical history,routine examination and medication, ECG and heart, HRV and APG record at admission, pre-discharge and every routine return visit within I year after discharge.Patients will also wear ECG and PPG (Photoplethysmography) band ever day after discharge, and collected the longitutinal data .All subjects will be tracked the medical adverse events in 1 years after discharge, and compare the characteristic and prognosis value of between patients with and without events. Therefore, our purpose of this study is to drive an effective outcome prediction model by non-invasive device, and establish a telecare model of patient with heart stent implantation to reducing medical adverse events.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2020

Longer than P75 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 28, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 2, 2020

Completed
18 days until next milestone

Study Start

First participant enrolled

July 20, 2020

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 20, 2022

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 20, 2024

Completed
Last Updated

July 23, 2020

Status Verified

June 1, 2020

Enrollment Period

2 years

First QC Date

June 28, 2020

Last Update Submit

July 21, 2020

Conditions

Keywords

Artificial IntelligenceNon-invasive Wearable DeviceTelecare Model of Patient,Acute Coronary Syndrome

Outcome Measures

Primary Outcomes (3)

  • death

    death

    Within a year

  • Restenosis

    Restenosis

    Within a year

  • heart failure

    heart failure

    Within a year

Secondary Outcomes (7)

  • heart disease re-hospitalization

    Within a year

  • Stroke re-hospitalization

    Within a year

  • Arrhythmia re-hospitalization

    Within a year

  • Physician adjusts medicine

    Within a year

  • Physician arranges examination early

    Within a year

  • +2 more secondary outcomes

Study Arms (1)

experimental group

Non-invasive Wearable Device, use ECG Wisdom bracelet

Device: use EKG Wisdom bracelet

Interventions

Non-invasive Wearable Device (use EKG Wisdom bracelet)

Also known as: control group (routine medical)
experimental group

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

We will enroll 400 patients who diagnosis of acute coronary syndrome and have been a heart stent surgery. And random allocation 200 experimental group (Non-invasive Wearable Device) and 200 control group (routine medical).

You may qualify if:

  • ≥ 20-year-old
  • Patients performing general metal stent surgery
  • Diagnosis of Acute Coronary Syndrome
  • Willing to sign the consent form of the subject and cooperate with the return visit
  • Those who are admitted to the hospital and enter the general ward can receive the first ECG heart sound examination

You may not qualify if:

  • \<20-year-old
  • Before the stent was installed, the same blood vessel had been used in patients with PCI (percutaneous coronary intervention) and CABG (Coronary artery bypass graft).
  • Those who cannot perform the first examination after being admitted to the hospital and entering the general ward
  • It is impossible to measure the group of ECG and heart sounds. For example, when using Pacemaker, the ECG showed ventricular tachycardia (VT) and Dextrocardia on admission.
  • Patients who are bedridden and have difficulty in cooperating with return visits
  • Any subject that the physician believes is at high risk for future uncooperative tracking
  • Direct participants in this program

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Acute Coronary Syndrome

Interventions

Control Groups

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Study Officials

  • Ju-Chi Liu, MD

    Chief, Internal of Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 28, 2020

First Posted

July 2, 2020

Study Start

July 20, 2020

Primary Completion

July 20, 2022

Study Completion

July 20, 2024

Last Updated

July 23, 2020

Record last verified: 2020-06